Risperidone treatment in preschool children with disruptive behavior disorders: A chart review study;Yıkıcı davranış bozuklukları olan okulöncesi çocuklarda risperidon tedavisi: Bir dosya tarama çalışması

Klinik Psikofarmakoloji Bulteni

Volumn 21, Issue 1, 2011, Pages 33-41

  Coskun, Murat ^a   Zoroglu, Suleyman Salih ^b   Oztu, Mucahit ^c  

^a Women's and Children's Hospital   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c PEDAM   (Turkey)

Author keywords

ADHD; Disruptive behavior disorders; Preschool children; Risperidone

Indexed keywords

LIPID; LIVER ENZYME; RISPERIDONE; TRIACYLGLYCEROL;

ABDOMINAL PAIN; AGGRESSION; ANGER; ANXIETY; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BODY WEIGHT; CHILD; CHILD DEVELOPMENT; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONDUCT DISORDER; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DISRUPTIVE BEHAVIOR; DIURNAL ENURESIS; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FECES INCONTINENCE; FEMALE; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HEADACHE; HIGH RISK BEHAVIOR; HUMAN; HYPERACTIVITY; HYPERPROLACTINEMIA; HYPERSALIVATION; INCREASED APPETITE; IRRITABILITY; MALE; MEDICAL RECORD REVIEW; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANT DISORDER; PATIENT REFERRAL; PERIORBITAL EDEMA; PICA; PRESCHOOL CHILD; PSYCHOSOCIAL CARE; RETROSPECTIVE STUDY; REVIEW; SEDATION; SIDE EFFECT; SKIN MANIFESTATION; SLEEP DISORDER; SWEATING; TIC; TREATMENT DURATION; TREATMENT RESPONSE; TRICHOTILLOMANIA; VOMITING;

EID: 79955603442     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: 10.5350/kpb-bcp201121106     Document Type: Review

References (37)

1. Pandina GJ, Aman MG, Findling RL. Risperidone in the Management of Disruptive Behavior Disorders. J Child Adolescent Psychopharmacol. 2006;4:379-392
2. Farrington DP: The Twelfth Jack Tizard Memorial Lecture. The development of offending and antisocial behaviour from childhood: Key findings from the Cambridge Study in Delinquent Development. J Child Psychol Psychiatry 1995;360:929-964
3. Kuperman S, Schlosser SS, Kramer JR, Bucholz K, Hesselbrock V, Reich T, Reich W. Developmental sequence from disruptive behavior diagnosis to adolescent alcohol dependence. Am J Psychiatry 2001;158:2022-2026
4. Lavigne JV, Cicchetti C, Gibbons RD, Binns HJ, Larsen L, DeVito C. Oppositional defiant disorder with onset in preschool years: longitudinal stability and pathways to other disorders. J Am Acad Child Adolesc Psychiatry. 2001;40:1393-1400
5. Keenan K, Wakschlag LS. Can a valid diagnosis of disruptive behavior disorder be made in preschool children? Am J Psychiatry. 2002;159:351-8
6. Keenan K, Wakschlag LS, Danis B, Hill C, Humphries M, Duax J, Donald R. Further evidence of the reliability and validity of DSM- IV ODD and CD in preschool children. J Am Acad Child Adolesc Psychiatry. 2007;46:457-468
7. Kim-Cohen J, Arseneault L, Caspi A, Tomás MP, Taylor A, Moffitt TE. Validity of DSM-IV conduct disorder in 4 1/2-5 year-old children: a longitudinal epidemiological study. Am J Psychiatry. 2005;162:1108-1117
8. Egger HL, Angold A: Common emotional and behavioral disorders in preschool children: Presentation, nosology, and epidemiology. J Child Psychol Psychiatry 2006;47:313-337
9. Campbell SB, Ewing LJ: Follow-up of hard-to-manage preschoolers: Adjustment at age 9 and predictors of continuing symptoms. J Child Psychol Psychiatry 1990;31: 871-88
10. DuPaul GJ, McGoey KE, Eckert TL, VanBrakle J. Preschool children with attentiondeficit/ hyperactivity disorder: Impairments in behavioral, social, and school functioning. J Am Acad Child Adolesc Psychiatry 2001;40:508-515
11. Moretti MM, Emmrys C, Grizenko N, Holland R, Moore K, Shamsie J, Hamilton H. The treatment of conduct disorder: Perspectives from across Canada. Can J Psychiatry 1997;42:637-648
12. Bennett KJ, Offord DR: Conduct disorder: can it be prevented? Curr Opin Psychiatry 2001;14:333-337
13. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63:679-685
14. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL; Risperidone Disruptive Behavior Study Group: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159:1337-1346
15. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Risperidone Conduct Study Group. Risperidone Conduct Study Group: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002;41:1026-1036
16. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, doubleblind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006;163:402-410
17. Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002;110: e34
18. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B; Risperidone Disruptive Behavior Study Group. Long-term, open- label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 2004;161:677-684
19. Croonenberghs J, Fegert JM, Findling RL. Risperidone Disruptive Behavior Study Group. Risperidone in children with disruptive behavior disorders and subaverage intelligence: A 1-year, open- label study of 504 patients. J Am Acad Child Adolesc Psychiatry 2005;44:64-72
20. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: Efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 2006;16:260-272
21. Haas M, Karcher K, Pandina GJ. Treating Disruptive Behavior Disorders with Risperidone: A 1-Year, Open-Label Safety Study in Children and Adolescents. J Child Adolescent Psychopharmacol 2008;18:337-345
22. Gleason MM, Egger HL, Emsile GJ, Greenhill LL, Kowatch RA, Lieberman AF, Luby JL, Owens J, Scahill LD, Scheeringa MS, Stafford B, Wise B, Zeanah CH: Psychopharmacological treatment for very young children: Contexts and guidelines J. Am. Acad. Child Adolesc. Psychiatry 2008; 46:1532- 1572.
23. Cesena M, Gonzalez-Heydrich J, Szigethy E, Kohlenberg TM, DeMaso DR. A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol 2002;12:337-345
24. Mukaddes NM, Abali O, Gurkan K. Short-term efficacy and safety of risperidone in young children with autistic disorder (AD). World J Biol Psychiatry. 2004;5:211-4
25. Masi G, Cosenza A, Mucci M, Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry. 2003;64:1039- 47
26. Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, Spitznagel E. Risperidone in Preschool Children with Autistic Spectrum Disorders: An Investigation of Safety and Efficacy J Child Adolescent Psychopharmacol 2006;16;575-587
27. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J. Open-Label, 8-Week Trial of Olanzapine and Risperidone for the Treatment of Bipolar Disorder in Preschool- Age Children. Biol Psychiatry 2005;58:589-594
28. Meighen KG, Hines LA, Lagges AM. Risperidone Treatment of Preschool Children with Thermal Burns and Acute Stress Disorder J Child Adolescent Psychopharmacol 2007;17;223-232
29. Olfson M, Crystal S, Huang C, Gerhard T. Trends in Antipsychotic Drug Use by Very Young, Privately Insured Children J. Am. Acad. Child Adolesc. Psychiatry, 2010;49:13-23
30. Sung V, Hiscock H, Sciberras E, Efron D. Sleep Problems in Children With Attention-Deficit/Hyperactivity Disorder: Prevalence and the Effect on the Child and Family. Arch Pediatr Adolesc Med. 2008;162:336-342
31. Mick E, Biederman J, Jetton J, Faraone SV. Sleep disturbance associated with attention deficit hyperactive disorder: the impact of psychiatric comorbidity and pharmacotherapy. J Child Adolesc Psychopharmacol. 2000;10:223-231
32. Corkum P, Moldofsky H, Hogg-Johnson S, Humphries T, Tannock R. Sleep problems in children with attention- deficit/hyperactive disorder: impact of subtype, comorbidity, and stimulant medication. J Am Acad Child Adolesc Psychiatry 1999;38:1285-93
33. Herguner S, Mukaddes NM. Risperidone-induced enuresis in two children with autistic disorder. J Child Adolesc Psychopharmacol. 2007;17:527-530
34. Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol. 2005;15:869-84
35. Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2001;40:1206-1214
36. Stevens JR, Kymissis PI, Baker AJL. Elevated Prolactin Levels in Male Youths Treated with Risperidone and Quetiapine J Child Adolesc Psychopharmacol. 2005;15: 893-900
37. American Academy of Child and Adolescent Psychiatry. Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder J. Am. Acad. Child Adolesc. Psychiatry 2007;46:894-921